1. At a Glance
Let’s not sugarcoat this. Krebs Biochemicals & Industries Ltd is the kind of stock that tests your faith, patience, and Excel skills — all at once.
Market cap sitting at ₹123 Cr, stock price at ₹57, down 43% in one year, with negative net worth, ROCE at -30%, OPM at -43%, and debt ballooned to ₹219 Cr. If numbers could scream, these would be asking for oxygen.
Q3 FY26 revenue came in at ₹7.27 Cr, down 36.6% YoY, while losses narrowed sequentially (PAT -₹3.13 Cr, QoQ improvement of ~60%). That’s like celebrating because the ship is sinking slightly slower.
Promoters still hold 72.74%, with Ipca Laboratories owning 49.65% — which is the single biggest reason this company is still discussed seriously and not as a pure case study in financial distress.
But here’s the twist: one plant shut down, pollution board drama, decade-long losses… and still, people whisper the word “revival”.
Let’s open the file properly. 🕵️♂️
2. Introduction
Krebs Biochemicals was incorporated in 1991, and for most of its listed life, it has behaved less like an API company and more like a financial endurance test.
The company manufactures Active Pharmaceutical Ingredients (APIs) and steroid intermediates — a space where margins should be healthy if scale, compliance, and execution cooperate. Unfortunately, Krebs has spent the last decade fighting everything except competitors:
- erratic operations
- regulatory shutdowns
- mounting debt
- continuous losses
- negative reserves that look like a horror movie sequel
Yet, unlike many microcap pharma disasters, Krebs has one unusual plot armour: Ipca Laboratories.
Ipca didn’t just buy shares — it infused ₹100 Cr via preference shares and converted 19.4 lakh warrants at ₹86/share, signaling long-term intent, not trading interest.
So the story is not “Is Krebs doing well?”
The real question is: Can Ipca drag Krebs back from the ICU?
3. Business Model – WTF Do They Even Do?
Krebs is an API and intermediate manufacturer, focused primarily on:
- Phenylephrine (yes, the nasal decongestant hero)
- Lovastatin & Simvastatin (cholesterol-lowering APIs)
- Androstenedione (steroid intermediate)
Revenue Mix FY22 (last clean disclosure):
- Phenylephrine: ~63%
- Simvastatin: ~13%
- Lovastatin: ~11%
- Services: ~11%
This is not a diversified API basket — this is dependency risk wearing a lab coat.
Upcoming products like Amlodipine, Cetirizine, Telmisartan, Orlistat, Serratiopeptidase sound great on paper, but until volumes show up in quarterly revenue, they remain PowerPoint molecules.
Manufacturing units
